NY-ESO-1 and cancer immunotherapy / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
;
(6): 371-377, 2008.
Article
in Chinese
| WPRIM
| ID: wpr-270686
ABSTRACT
NY-ESO-1 is an important member of cancer-testis antigen family and is widely distributed among many cancer types. As a tumor-specific antigen with the strongest immunogenicity so far identified, it can induce spontaneous antibody and T-cell responses in patients with NY-ESO-1-positive tumors. Therefore, it has been a good vaccine candidate in the immunotherapy against many malignancies. This article reviews the recent research advances in NY-ESO-1 and its relevant vaccines.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Therapeutics
/
Clinical Trials as Topic
/
Cancer Vaccines
/
Therapeutic Uses
/
Allergy and Immunology
/
Genetics
/
Immunotherapy
/
Membrane Proteins
/
Antigens, Neoplasm
/
Neoplasms
Limits:
Humans
Language:
Chinese
Journal:
Acta Academiae Medicinae Sinicae
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS